UK Regulatory Science community meets to discuss the future of UK Medicine Regulation

UK Bioindustry Association (BIA) host industry and MHRA leaders at “The Future of UK Regulation Conference 2023” 

London, UK, 3 October, 2023 -  Leaders in medicines regulatory science are meeting to chart the course for the future of UK medicine regulation on 5 October at 11 Cavendish Square, London.  

The high-profile event is bringing together over 200 industry thought leaders, international stakeholders and regulatory experts with the senior leadership of the UK’s healthcare regulatory agency, the MHRA.  

Conference participants will be able to hear directly from expert speakers, including Dr June Raine DBE, CEO of the MHRA, Lord James O'Shaughnessy, who conducted a review into clinical trial effectiveness for the government earlier this year, and Professor Lucy Chappell, head of the National Institute for Health Research (NIHR).  

The conference will provide the latest developments, tackling insightful topics, at a time of significant change, challenge and opportunity: 

  • Getting UK clinical trials back on track 
  • The new international recognition framework for medicines – enabling access to innovation as a UK USP  
  • Latest thinking in approaches to the regulation of novel technologies – with a focus on how the application of artificial intelligence to the drug discovery and development process is best handled.   

Commenting on the conference, Steve Bates, CEO of the BIA said: “By bringing together the great minds we have in UK regulatory science, from both our regulatory agency and our leading life science companies, I believe the UK has an opportunity to rapidly develop practical regulatory procedures in new areas that can play a key role on the world stage.  

“The greatest strength of the UK life science ecosystem is innovation, and we know that it’s the intersection of new technologies, the machine learning from artificial intelligence allied to the greater understanding of cell biology from institutions like the Francis Crick Institute that is driving the next generation of companies, products and services.  

“With a laser-like focus on our strengths and a regulatory science mindset, I have every expectation that a practical collaborative innovation agenda will emerge from the day’s expert discussions.” 

Dr June Raine DBE, CEO of MHRA said: “At a time of ever-evolving challenges for global health, experts and industry leaders from the UK continue to provide pioneering solutions, keeping this country at the centre of global healthcare innovation. 

“To enable these world-leading industry efforts, regulators in the UK are also innovating hard, through new pathways and support systems to ensure patient access to the safe and effective products they need at the earliest opportunity. 

“By bringing together regulators and industry leaders through the BIA to address the biggest global healthcare challenges, we can continue to establish the UK as a world-leading home for the global life sciences industry and a place where medical innovation can flourish.” 

- Ends. -

 

Media Contacts

For more information or to attend, contact Alina O’Keeffe, Head of Marketing and Membership Communications, BIA on [email protected]  

Limited tickets for regulatory professionals are available.

 

More news and updates 

New boost for TechBio companies seeking investment

The Francis Crick Institute’s start-up accelerator KQ Labs and the UK Bioindustry Association (BIA) have launched a new programme to support growing companies working at the interface of biology and data technologies.

State of the Discovery Nation report reveals the extent of sector's perfect storm

New report 'State of the Discovery Nation: Fostering a Dynamic, Sustainable Medicines Discovery Sector’ says the sector must work together to de-risk funding in medicines discovery and attract more investors.

BIA teams up with top UK engineering biology stakeholders to champion the UK at SynBioBeta 2024

BIA is gearing up for a prominent presence at SynBioBeta 2024, the world's leading conference for engineering biology. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's engineering biology companies from 6-9 May in San Jose, California.

Post-Brexit border paperwork and inspections postponed for life sciences sector

Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

BIA responds to Spring Budget 2024: highlights for UK life sciences

Three highlights for UK life sciences: first, the new expert advisory panel for the HMRC is a smart way to maximise the efficiency of R&D tax relief support for life science innovators; secondly, Alan Marchington’s ICG winning the LIFTs scheme shows real movement to unlock pension funds for life sciences; thirdly, AstraZeneca’s investment in next-generation manufacturing in Speke and Cambridge shows the strength of our ecosystem.

Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

 

More within